FDA Withdraws Approval of Pepaxto in Multiple Myeloma.

The article focuses on the U.S. Food and Drug Administration' (FDA) withdrawal of approval for Pepaxto in treating multiple myeloma due to the failure of its confirmatory study to demonstrate clinical benefit and safety. Topics discussed include the timeline of events leading to the withdrawal, the concerns raised by regulators regarding the drug's efficacy and safety, and Oncopeptides' response to the decision.